




Profound paresthesia-free pain relief within minutes¹


FAST™ Therapy



► PROFOUND PAIN RELIEF AND FUNCTIONAL IMPROVEMENT THAT LASTS.

Conventional paresthesia-free therapy takes time to wash in. With FAST, or Fast Acting Sub-perception Therapy, patients can experience significant pain relief before they leave your clinic, giving you and your patients confidence in their spinal cord stimulation (SCS) therapy.^{2,3}

- ⊕ Why Using FAST
- ⊕ How FAST Works
- ⊕ Key Elements of FAST
- ⊕ Key Clinical Data





IMMEDIATE PAIN RELIEF AND DIRECT PATIENT FEEDBACK

- ✓ Send your patients home confidentially.
- ✓ Increased trust and confidence in the therapy.



SIMPLIFIED THERAPY AND PATIENT MANAGEMENT

- ✓ Freed up time for you and your patients' by optimizing the therapy from the beginning.
- ✓ Low energy consumption for preserved device longevity and less need to recharge.



QUICK AND EASY TO PROGRAM


- ✓ Immediately visible results that are quick to set-up and easy to reproduce.





BASELINE PAIN

In the Gate Control theory, small sensory fibers send pain signals to the Wide Dynamic Range (or WDR) neurons, which are then transmitted to the brain.



Baseline

Conventional SCS

Illumina 3D™


FAST™





CONVENTIONAL SCS

Conventional SCS activates large sensory fibers from the center area of pain and some from the surrounding region, causing both inhibition and excitation.



Baseline



Conventional SCS



Illumina 3D™




FAST™





PARESTHESIA SCS: PRECISE TARGETING

With tight contact spacing, MICC, and Illumina 3D™, we can activate more of the surrounding area, leading to greater inhibition and less pain.¹



Baseline



Conventional SCS



Illumina 3D™




FAST™





PRECISE TARGETING + PROPER DOSE = FAST

With proper neural dosing, we reduce center excitation while retaining surround inhibition, leading to profound pain relief.¹



Baseline



Conventional SCS






Illumina 3D™



FAST™





PRECISE TARGET

Proprietary Targeting Algorithms

- *Multiple Independent Current Control*
- *Illumina 3D™*
- *Tight Spaced Leads*
- *Active Recharge at Low Rate*

PROPER NEURAL DOSE

Neural Dosing Expertise

- *Frequency*
- *Pulse Width*
- *Amplitude*

Fast

Acting

Sub-perception


Therapy





FAST THERAPY IS BACKED BY PUBLISHED REAL-WORLD DATA¹, PRECLINICAL DATA⁴ AND COMPUTATIONAL MODELING⁵

► Published Real World Data Demonstrate Profound Paresthesia-Free Pain Relief in Minutes with FAST Therapy¹




After activation of FAST Therapy

- Overall pain was reduced by a mean 5.2 ± 0.3 points versus pre-FAST Therapy activation within 11.2 ± 1.9 minutes ($N = 34$).[†]
- Overall pain was reduced by a mean 7.0 ± 0.4 points ($N = 41$, $p < 0.0001$) at 6 month follow-up.





► FAST provides clinically meaningful pain relief while preserving device longevity and improving battery consumption management⁶




- All FAST stimulation options show >50% responder rate.
- FAST responders achieve profound pain relief (NRS <2) with the use of all FAST stimulation options.
- FAST stimulation energy consumption is 95% lower compared to conventional Sub-perception SCS.





FAST PAIN RELIEF SUSTAINED OUT TO 2 YEARS³

► More than 70% NRS score reduction for overall pain from baseline to 2 years follow-up*



- A pain improvement of ≥ 5 -point improvement was noted in patients after 1-year and 2-year follow-up.

* Analysis of Quality of life and functional outcomes improvement at 2-year follow-up are ongoing.



THE WAVEWRITER ALPHA™ SCS SYSTEM:

WaveWriter Alpha™ offers both rechargeable and non-rechargeable systems – each with a choice of 16 or 32 contacts. All devices also include:



Advanced Therapies



Full-Body MRI* Access




Bluetooth® Connectivity




PERSONALIZED THERAPIES, PROFOUND RESULTS

With WaveWriter Alpha™ comes advanced therapy options.




FAST Therapy

FAST, or Fast Acting Sub-perception Therapy, targets a new and distinct mechanism of action in SCS⁵ and delivers paresthesia-free pain relief in minutes.



Contour Therapy


Our optimized Contour Therapy delivers broad, energy efficient, paresthesia-free coverage across multiple neural targets.



Multiple MOAs

Explore the various "mechanisms of action" of our therapies - or the means by which they target pain in the spinal cord.





▶ INDICATIONS FOR USE

* Difference calculated based on pre- and post follow-up with data per patient.

† Time interval data were only available for 34 out of the 41 total patients assessed during the FAST Therapy programming session.

1. Metzger et al. A novel fast-acting sub-perception spinal cord stimulation therapy enables rapid onset of analgesia. in patients with chronic pain, Expert Review of Medical Devices 2021.

2. Anitescu M., et al. Clinical impact of a novel fast-acting subperception SCS therapy engaging surround inhibition (FAST prospective study), NANS 2023.

3. Bayerl S., et al. Clinical Outcomes Using A New Fast-Acting Sub-Perception Therapy For Chronic Pain: A Multicenter European Observational Real-World Study, NANS 2023.

4. Gilbert J, Titus ND, Zhang TC, Esteller R. Grill WM. Mechanisms of Low Frequency Sub-Perception Spinal Cord Stimulation. INS 2022.

5. FAST MOA computational modeling by Dr. Warren Grill's lab at Duke University. Gilbert et al. Computational modeling predicts dorsal columns are involved in fast-acting sub-perception spinal cord stimulation (SCS). SFN 2021.

6. North J. Enhanced Efficiency and Spinal Cord Stimulation Outcomes Using Fast-Acting Sub-Perception Therapy (FAST) for Chronic Pain. INS 2022.



*The WaveWriter Alpha™ SCS System provides safe access to full-body MRI scans when used with specific components and the patient is exposed to the MRI environment under the defined conditions in the ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha and WaveWriter Alpha Prime Spinal Cord Stimulator System.

The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Boston Scientific Neuromodulation Corporation is under license.

Product available in the European Economic Area (EEA) only. Please check availability with your local sales representative or customer service.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

